Significant clinical and imaging predictors of PD HCC, including patient demographics, etiology, Child–Pugh stage, tumor markers (i.e., AFP, CA199, CEA), laboratory indexes (e.g., ALT, AST, TBIL), LI-RADS v2018 feature and other imaging features which had been reported to correlate with the degree of tumor differentiation, tumor burden, and HCC aggressiveness (e.g., marked HBP hypointensity, peritumoral hypointensity in HBP, and complete capsule), were analyzed in the univariate analysis. The gene discussed is CEACAM5; the disease is neoplasm.